|
1
|
Minegishi Y, Takenaka K, Mizutani H, Sudoh
J, Noro R, Okano T, Azuma A, Yoshimura A, Ando M, Tsuboi E, et al:
Exacerbation of idiopathic interstitial pneumonias associated with
lung cancer therapy. Intern Med. 48:665–672. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Minegishi Y, Sudoh J, Kuribayasi H,
Mizutani H, Seike M, Azuma A, Yoshimura A, Kudoh S and Gemma A: The
safety and efficacy of weekly paclitaxel in combination with
carboplatin for advanced non-small cell lung cancer with idiopathic
interstitial pneumonias. Lung Cancer. 71:70–74. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shukuya T, Ishiwata T, Hara M, Muraki K,
Shibayama R, Koyama R and Takahashi K: Carboplatin plus weekly
paclitaxel treatment in non-small cell lung cancer patients with
interstitial lung disease. Anticancer Res. 30:4357–4361.
2010.PubMed/NCBI
|
|
4
|
Enomoto Y, Inui N, Kato T, Baba T,
Karayama M, Nakamura Y, Ogura T and Suda T: Low forced vital
capacity predicts cytotoxic chemotherapy-associated acute
exacerbation of interstitial lung disease in patients with lung
cancer. Lung Cancer. 96:63–67. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Socinski MA, Bondarenko I, Karaseva NA,
Makhson AM, Vynnychenko I, Okamoto I, Hon JK, Hirsh V, Bhar P,
Zhang H, et al: Weekly nab-paclitaxel in combination with
carboplatin versus solvent-based paclitaxel plus carboplatin as
first-line therapy in patients with advanced non-small-cell lung
cancer: Final results of a phase III trial. J Clin Oncol.
30:2055–2062. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Raghu G, Collard HR, Egan JJ, Martinez FJ,
Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, et
al: An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary
fibrosis: Evidence-based guidelines for diagnosis and management.
Am J Respir Crit Care Med. 183:788–824. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ozawa Y, Suda T, Naito T, Enomoto N,
Hashimoto D, Fujisawa T, Nakamura Y, Inui N, Nakamura H and Chida
K: Cumulative incidence of and predictive factors for lung cancer
in IPF. Respirology. 14:723–728. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kudoh S, Kato H, Nishiwaki Y, Fukuoka M,
Nakata K, Ichinose Y, Tsuboi M, Yokota S, Nakagawa K, Suga M, et
al: Interstitial lung disease in Japanese patients with lung
cancer: A cohort and nested case-control study. Am J Respir Crit
Care Med. 177:1348–1357. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Watanabe N, Nakahara Y, Taniguchi H,
Kimura T, Kondoh Y, Kataoka K and Sakamoto K: Crizotinib-induced
acute interstitial lung disease in a patient with EML4-ALK positive
non-small cell lung cancer and chronic interstitial pneumonia. Acta
Oncol. 53:158–160. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Watanabe N, Taniguchi H, Kondoh Y, Kimura
T, Kataoka K, Nishiyama O, Kondo M and Hasegawa Y: Efficacy of
chemotherapy for advanced non-small cell lung cancer with
idiopathic pulmonary fibrosis. Respiration. 85:326–331. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kenmotsu H, Naito T, Kimura M, Ono A,
Shukuya T, Nakamura Y, Tsuya A, Kaira K, Murakami H, Takahashi T,
et al: The risk of cytotoxic chemotherapy-related exacerbation of
interstitial lung disease with lung cancer. J Thorac Oncol.
6:1242–1246. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Azuma Y, Tamiya M, Shiroyama T, Osa A,
Takeoka S, Morishita N, Suzuki H, Okamoto N, Hirashima T and Kawase
I: Nanoparticle albumin-bound paclitaxel+carboplatin therapy for
small cell lung cancer combined with squamous cell carcinoma and
interstitial lung disease. Intern Med. 54:2911–2913. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gupta N, Hatoum H and Dy GK: First line
treatment of advanced non-small-cell lung cancer-specific focus on
albumin bound paclitaxel. Int J Nanomedicine. 9:209–221.
2014.PubMed/NCBI
|
|
14
|
Asai N, Katsuda E, Hamanaka R, Kosaka K,
Matsubara A, Nishimura M, Tanaka H, Yokoe N, Takahashi A, Yamaguchi
E and Kubo A: The ATS/ERS/JRS/ALAT statement ‘IPF by HRCT’ could
predict acute exacerbation of interstitial lung disease in
non-small cell lung cancer. Tumori. 103:60–65. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Walsh SL, Calandriello L, Sverzellati N,
Wells AU and Hansell DM: UIP Observer Consort: Interobserver
agreement for the ATS/ERS/JRS/ALAT criteria for a UIP pattern on
CT. Thorax. 71:45–51. 2016. View Article : Google Scholar : PubMed/NCBI
|
